- Home
- RVMD vs WES Comparison
RVMD vs WES Comparison
Compare RVMD & WES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVMD | WES |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 16.0B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RVMD | WES |
|---|---|---|
| Price | $146.92 | $42.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 7 |
| Target Price | ★ $140.84 | $41.71 |
| AVG Volume (30 Days) | ★ 3.7M | 1.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 8.81% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $3,843,403,000.00 |
| Revenue This Year | N/A | $6.42 |
| Revenue Next Year | $533.02 | $6.99 |
| P/E Ratio | ★ N/A | $14.73 |
| Revenue Growth | N/A | ★ 6.61 |
| 52 Week Low | $34.00 | $36.25 |
| 52 Week High | $155.70 | $44.74 |
Technical Indicators
Market Signals| Indicator | RVMD | WES |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 60.14 |
| Support Level | $93.39 | $39.62 |
| Resistance Level | $152.85 | $44.74 |
| Average True Range (ATR) | 7.19 | 0.77 |
| MACD | -0.47 | 0.22 |
| Stochastic Oscillator | 61.79 | 75.34 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About WES Western Midstream Partners LP
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma) and Texas.